Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of teclistamab or talquetamab plus daratumumab and lenalidomide versus DRd in transplant-ineligible newly diagnosed multiple myeloma
CTR20241434Phase 3Active
- Sponsor
- Janssen Research & Development
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of teclistamab, talquetamab, daratumumab, lenalidomide, dexamethasone in multiple myeloma (MM), sponsored by Janssen Research & Development. Started Jun 2024; status: active.
02
Drugs
teclistamabtalquetamabdaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20241434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241434.